Assessing the potential impact of President Trump’s “most favored nation” drug pricing policy on biopharma companies.
Insights
Our latest thinking on the themes shaping today’s investment landscape. Explore timely updates, quarterly features and in-depth analysis straight from our experts.
A new paradigm founded upon fewer rules-based US policies points to a more uncertain global economy and could even signal US recession, but what does it mean for the emerging markets?
Three reasons agency MBS look attractive right now.
With large capital reserves, an improving regulatory backdrop, and positive growth trends, many financial firms look prepared to withstand a potential recession.
Why we favor quality over speculative growth in today’s uncertain environment.
Facing tariff-related tension on both sides of its dual mandate, the Fed waits for additional clues on the fate of the U.S. economy.
A discussion on the global landscape of fixed income markets and where we think investors may find attractive risk-adjusted returns.
These company characteristics could help investors win out over looming tariffs and federal funding cuts in the healthcare sector.
Is ESG dead? Far from it – but misconceptions abound.
Defensive stocks have outperformed, but cyclicals still offer higher growth potential.
How has relative value shifted across fixed income sectors amid tariff-related volatility and what does this mean for asset allocation?